Megan Sanders, Chief Executive Officer at Thoracic Oncology Group of Australasia, shared a post on LinkedIn:
“MSAC has declined public funding for ctDNA testing in NSCLC, which is generating a lot of discussion across the sector.
This is a good example of where clinical practice, emerging evidence and policy settings are not yet fully aligned.
Clinicians are already managing patients where tissue is limited or unavailable, where time to treatment matters, and where precision medicine based on ctDNA analysis, if that’s all that is available, may offer life saving treatment.
The next step is not just debate but generating the right evidence and building pathways that allow appropriate access.
At TOGA, this is a key focus, including through ASPiRATION-2 Liquid and our broader genomics work.
Worth a read.”
